4//SEC Filing
Smith Michael David 4
Accession 0001209191-21-029341
CIK 0001348911other
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 5:49 PM ET
Size
8.7 KB
Accession
0001209191-21-029341
Insider Transaction Report
Form 4
Smith Michael David
Sr. VP, Development
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-04-28−10,014→ 30,096 totalExercise: $8.39Exp: 2026-11-21→ Common Stock (10,014 underlying) - Exercise/Conversion
Common Stock
2021-04-28$8.39/sh+10,014$84,017→ 10,014 total - Sale
Common Stock
2021-04-28$25.76/sh−10,014$257,983→ 0 total
Footnotes (1)
- [F1]The option is fully vested.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001777800
Filing Metadata
- Form type
- 4
- Filed
- Apr 29, 8:00 PM ET
- Accepted
- Apr 30, 5:49 PM ET
- Size
- 8.7 KB